Vivimed Labs share news, announcements and annual reports
NSE: VIVIMEDLABBSE: 532660Pharmaceuticals & BiotechnologySmall Cap
Vivimed Labs Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2005
Last close ₹5.53down ₹0.11 (1.95%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹5.64.
30 Oct: open ₹5.62, high ₹5.64, low ₹5.53
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹46 Cr3,293rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 3,267
Vivimed Labs share news and announcements
642 announcements, routine notices left out, newest first. Page 11 of 13.
Mar 2013
22 Mar · Business
Management Committee of the Board of Directors of the Company at its meeting held on March 22, 2013, has allotted 21,26,984 Equity Shares of Rs.10/- each fully paid up at a premium of Rs.305/- per share to NYLIM Jacob Ballas India FUND III, LLC (Address : IFS Court, Twentyeight, Cybercity, Ebene, Mauritius) against conversion of 6,70,000 CCPS (face value Rs. 1000/- each) held by them. With the allotment of the said shares, the Equity base of the Company stands increased from present level of 139,33,942 (Nos.) to 160,60,926 (Nos.) Equity shares of Rs.10/- each.
Feb 2013
14 Feb · Board meeting
5 Feb · Board meeting
Inter alia to consider, approve and take on record the Unaudited Financial Results of the Company for the quarter ended December 31, 2012.
Jan 2013
8 Jan · Board meeting
Nov 2012
6 Nov · Board meeting
Inter alia, to consider the Unaudited Financial Results for the quarter ended September 30, 2012.5 Nov · Change in Company Secretary
Vide letter dated October 30, 2012 that Mr. Fahim Aslam Khan, Company Secretary is replaced by Mr. K. Yugandhar, Company Secretary.
Oct 2012
Sep 2012
4 Sep · Meeting
Annual General Meeting of the Company will be held on September 27, 2012 and the Register of members & share transfer books of the company will remain closed from September 25, 2012 to September 27, 2012(both days inclusive) for the purpose of Final Dividend.
Aug 2012
6 Aug · Board meeting
Inter alia to consider, approve and take on record the unaudited financial results of the Company for the quarter ended June 30, 2012.
May 2012
31 May · Dividend
Board of Directors of the Company at its meeting held on May 30, 2012 has recommended : (1) A final dividend of 3.5% on Compulsorily Convertible and Cumulative Preference Shares (CCPS's) on pro-rata basis for the financial year 2011-12; (2) A final dividend of Rs. 3/- per share (30%) on equity shares for the financial year 2011-12.17 May · Board meeting
Inter alia, to consider the Audited Financial Results for financial year ended March 31, 2012 and to consider recommendation of final dividend for financial year ended March 31, 2012.12 May · Results
Company will be publishing audited financial results for the financial year ended March 31, 2012, within 60 days from the end of the financial year.
Apr 2012
4 Apr · Legal
Vide its letter dated April 04, 2012 regarding "This has reference to reports in a leading business television channel that 'Vivimed Labs Limited' may do placement to Lo'real, the company would like to clarify that said reports are untrue."
Mar 2012
Feb 2012
Jan 2012
30 Jan · Board meeting
Inter alia to consider, approve and take on record the Unaudited Financial Results of the Company for the quarter ended December 31, 2011.
Dec 2011
Nov 2011
16 Nov · Board meeting
Board of Directors of the Company at its meeting held on November 14, 2011 have accepted resignation of Mr. Krishna Yeachuri and Mr. D Hanumantha Rao as Directors of the Company, And have Appointed Mr. Chunduri Ramakrishna and Mr. Srinivas Chidambaram as Additional Director.7 Nov · Board meeting
Inter alia to consider, approve and take on record the unaudited financial results of the Company for the quarter and half year ended September 30, 2011.
Oct 2011
24 Oct · Updates
14,90,000 convertible warrants allotted on April 24, 2010 have been converted into 14,90,000 equity shares of the Company at the meeting of Management Committee of the Board of Directors of 'Vivimed Labs Limited' held on October 23, 2011.3 Oct · Updates
Company, in consolidating its segment of domestic pharmaceutical business, has acquired 100% equity stake in Klar Sehen Pvt. Ltd., (KSPL), a 30 year old Kolkata based Pharmaceutical Company with strong marketing presence in North East, Bihar and Andhra Pradesh. KSPL operates in a niche ophthalmic segment and owns about 50 trademarks and some very well known brands such as Renicol, Lysicon-V, Care Tears, Dexacort etc, in eye care segment. In a research conducted by C-Marc (India) Pvt Ltd for the period Nov-Feb 2011, KSPL for its wide range of Ophthalmic products has bagged an All India corporate standing rank of No. 1 in the East Zone and bagged a rank of No. 5 in India (in Indian, Dist HQ & Extra-Urban and rural markets). KSPL has cGMP compliant manufacturing facilities at Kolkata, Hyderabad and also has arrangements to manufacture some of its products in Uttaranchal. KSPL presently operates from its headquarters in Kolkata with over 150 medical sales professionals. Vivimed's acquisition of KSPL complements its strategy to increase its domestic presence in specialty pharmaceutical areas, its extensive knowledge and experience in manufacturing, R&D will help grow this business to new levels.
Sep 2011
29 Sep · Business
Management Committee of Board of Directors of the Company at their meeting held on September 29, 2011 has allotted 1830137 Equity Shares of Rs.10/- to Kitara PIIN 1102.23 Sep · Business
Management Committee of Board of Directors of the Company at their meeting held on September 22, 2011, has allotted 6,70,000 Compulsorily Convertible and Cumulative Preference Shares (CCPSs) of Rs. 1000/- to Nylim Jacob Ballas India Fund III LLC.